# Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.

> **NCT00554086** · PHASE2 · COMPLETED · sponsor: **Canadian Urology Research Consortium** · enrollment: 65 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Escalating dose of Casodex from 50mg daily to 150 mg daily

## Key facts

- **NCT ID:** NCT00554086
- **Lead sponsor:** Canadian Urology Research Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2009-09
- **Final completion:** 2010-09
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2011-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00554086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00554086, "Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00554086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*